Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Murali Janakiram, MD, MS
Videos
Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Salomon Manier, MD, PhD
Conference Coverage
Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM  
07/02/2024
At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.
At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.
At the 2024 ASCO Annual Meeting,...
07/02/2024
Oncology
Luciano Costa, MD
Videos
Second-Line Cilta-cel Improves Outcomes for Patients With Functional High-Risk Multiple Myeloma vs Standard of Care Therapy
06/07/2024

Featuring Luciano Costa, MD

Featuring Luciano Costa, MD
Cilta-cel improved outcomes for patients with lenalidomide-refractory functional high-risk multiple myeloma vs standard of care, according to data presented by Luciano Costa, MD, at the 2024 ASCO Annual Meeting.
Cilta-cel improved outcomes for patients with lenalidomide-refractory functional high-risk multiple myeloma vs standard of care, according to data presented by Luciano Costa, MD, at the 2024 ASCO Annual Meeting.
Cilta-cel improved outcomes for...
06/07/2024
Oncology
Maria-Victoria Mateos, MD, PhD
Conference Coverage
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Efficacy for Patients With R/R Multiple Myeloma
06/07/2024

Featuring Maria-Victoria Mateos, MD, PhD

Featuring Maria-Victoria Mateos, MD, ...
Maria-Victoria Mateos, MD, PhD, presents results from the phase 3 DREAMM-7 trial, which demonstrated the efficacy of belantamab mafodotin plus bortezomib and dexamethasone as a potential new standard of care for patients with R/R MM.
Maria-Victoria Mateos, MD, PhD, presents results from the phase 3 DREAMM-7 trial, which demonstrated the efficacy of belantamab mafodotin plus bortezomib and dexamethasone as a potential new standard of care for patients with R/R MM.
Maria-Victoria Mateos, MD, PhD,...
06/07/2024
Oncology
Robert Rifkin, MD, Rocky Mountain Cancer Centers
Conference Coverage
Prophylactic Tocilizumab Prior to Outpatient Step-Up Administration of Teclistamab Lowers CRS Among Patients With R/R MM
06/04/2024

Featuring Robert Rifkin, MD

Featuring Robert Rifkin, MD
Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.
Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.
Robert Rifkin, MD, discusses...
06/04/2024
Oncology
Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/10/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/10/2024
Oncology
Noa Biran, MD, John Theurer Cancer Center
Q&As
Step-Up Dosing for Multiple Myeloma Treatment in the Outpatient Setting
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the...
05/06/2024
Oncology
Noa Biran, MD, Hackensack Meridian Health
Conference Coverage
Evaluating Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a...
05/06/2024
Oncology
Gareth Morgan, MD, NYU Langone Medical Center
Conference Coverage
Assessing the Strength of Minimal Residual Disease Testing for Patients With Multiple Myeloma
04/19/2024

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in...
04/19/2024
Oncology
David Siegel, MD, PhD, Hackensack Meridian Health
Conference Coverage
Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65
04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates &...
04/19/2024
Oncology

Advertisement

Advertisement

Section Editor

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement